Healthcare Industry News: Magnetic Resonance Imaging
News Release - February 19, 2009
CAD with Full-Field Digital Mammography Shows High Sensitivity in Assisting Radiologists to Detect Early-Stage Breast CancersPositive Data on iCAD’s SecondLook(R) Computer-Aided Detection for Mammograms Published in the American Journal of Roentgenology
NASHUA, N.H.--(HSMN NewsFeed)--iCAD, Inc. (Nasdaq: ICAD ), an industry leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced publication of peer-reviewed data on its SecondLook Computer-Aided Detection (CAD) technology in the February issue of the American Journal of Roentgenology (Volume 192, Issue 2). The study, by Juliette The, MD and Kathy Schilling, MD included 123 cancers detected with full-field digital mammography (FFDM).
The article, titled “Detection of Breast Cancer with Full-Field Digital Mammography and Computer-Aided Detection,” found the following:
- CAD with FFDM showed a high sensitivity in identifying cancers
- The SecondLook CAD correctly marked 94% of biopsy-proven cancers
- The sensitivity of iCAD’s SecondLook CAD was not dependent on the size of the tumor; it was equally accurate with small and large lesions
SecondLook CAD for digital mammography was designed and developed using thousands of cancer and normal studies, providing a powerful digital CAD performance. SecondLook Digital is optimized for leading digital mammography systems including GE Healthcare, Siemens Medical Systems, Fujifilm Medical Systems, IMS Giotto, Agfa Healthcare, and Sectra. In addition, iCAD’s SecondLook Digital provides the most powerful flexible Digital Imaging and Communications in Medicine (DICOM) connectivity solution enabling universal compatibility with leading Picture Archiving Communication System (PACS) and Review Workstations.
“The impressive results of this study reflect the strong performance we have demonstrated with our SecondLook technology, and it provides radiologists with key data supporting the benefits of using CAD with digital mammography,” said Ken Ferry, President and CEO of iCAD.
The American Journal of Roentgenology (R) is the highly respected peer-reviewed journal of the American Roentgen Ray Society. The society has been a forum for progress in radiology since shortly after the discovery of the X-ray and is dedicated to the goal of the advancement of medicine through the science of radiology and its allied sciences.
About SecondLook Digital
SecondLook Digital provides the most effective CAD technology that is designed to assist the radiologist in distinguishing cancers from other anomalies in the breast. SecondLook Digital is extremely proficient at detecting subtle cancers, or those that are most likely to be missed. SecondLook also provides workflow efficiencies that can improve the flow of patients within a mammography center.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 2,700 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.